





AGENDA

Friday, June 3

| MA 00:80 | 08:10 AM | Introductions & House Keeping | Dr. Simon Jackson |
|----------|----------|--|---------------------|
| 08:10:00 | 08:30:00 | Intervention for severe asymptomatic AS: A critical review of the literature. There is a growing consensus that severe and very severe AS without symptoms should undergo AV replacement. This review will focus on the clinical data supporting this evolving change in practice including identifying patients who were studied, quantifying the harm prevented and the complications incurred with early intervention, and reviewing current durability data for iprosthetic AVR. | Dr. Brent McGrath |
| 08:30:00 | 08:40:00 | Audience Interaction & Participation | |
| 08:40:00 | 09:00:00 | Mitra-clip: What's new? Nova Scotia has been implementing a Mitraclip program. How can we access this service? What tests need to be performed first? Who are the appropriate patients for review, and how is suitability determined? What is the early experience? What do we expect going forward? | Dr. Osama Elkhateeb |
| 09:00:00 | 09:10:00 | Audience Interaction & Participation | |
| 09:10:00 | 09:40:00 | HFrEF after an ACEi, betablocker and mineralocorticoid receptor antagonist: What is next? This session will pose a series of clinical conundrums in the management of HFrEF. Some questions have no clear RCT data, but are real scenarios that we will ask our speaker to address. Assume you patient has private insurance or does not, does this influence the addition of ARNI, SGLT2i, or ivabradine? Can we "personalize" choices in an evidenced base manner? What is the clinical trial evidence supporting starting many drugs at once, versus the clinical trial evidence of stepwise addition, if any? What should you do when seeing a new patient who has been "stable" for 10 years on 2 drugs in follow up with an EF of 30 and FC 1 or 2 and no change? Is there evidence to support your decision to add on more medication? | Dr. Miroslaw Rajda |
| 09:40:00 | 09:55:00 | Audience Interaction & Participation | |
| 09:55:00 | 10:25:00 | Morning Nutrition Break & Exibits | |

| 10:25:00 | 10:45:00 | New AF: when to cardiovert? | Dr. Martin Gardner |
|----------|----------|--|----------------------|
| | | New guidelines have an increased emphasis on a "trial of cardioversion" in patients with new AF. How and when should you practically do this? Are there patients who should always or never have a trial of cardioversion? How do you determine post cardioversion if sinus is truly better or accept rate control when AF recurs? | |
| 10:45:00 | 10:55:00 | Audience Interaction & Participation | |
| 10:55:00 | 11:10:00 | COVID and vaccine myocarditis: recognition, investigation and treatment. | Dr. Doug Hayami |
| | | There has been much publicity about covid and vaccine related myocarditis. In this review, we will learn the etiology, epidemiology, diagnostic and treatment algorithm for this complication, with specific emphasis on who needs more advanced testing. | |
| 11:10:00 | 11:25:00 | Audience Interaction & Participation | |
| 11:25:00 | 11:45:00 | Diagnosis and management of angina with no coronary artery disease? | Dr. Sharon Mulvagh |
| | | The story is typical, but there is no coronary disease. What do you do next? | |
| 11:45:00 | 11:55:00 | Audience Interaction & Participation | |
| 11:55:00 | 12:45:00 | Lunch | |
| 12:45:00 | 13:15:00 | Perioperative myocardial infarction: What is new for immediate assessment and management? | Dr. PJ Devereaux |
| 13:15:00 | 13:30:00 | Audience Interaction & Participation | |
| 13:30:00 | 13:45:00 | Pulmonary Hypertension: Echo diagnosis | Dr. Robbie Stewart |
| | | We will review the echo diagnosis of pulmonary hypertension and clues to determining etiology. | |
| 13:45:00 | 13:50:00 | Pulmonary Hypertension: Initial work up | Dr. Simon Jackson |
| | | A brief review of the initial work up and when to send urgently for catheter-based diagnosis. | |
| 13:50:00 | 14:00:00 | Audience Interaction & Participation | |
| 14:00:00 | 14:15:00 | LV thrombus: an unclear problem | Dr. Chris Koilpillai |
| | | How do you best find an LV thrombus? When should you look? What do you do if one is found? Is there any evidence to support NOAC's, or indeed any evidence to support warfarin. | |
| 14:15:00 | 14:25:00 | Audience Interaction & Participation | |
| 14:25:00 | 14:45:00 | Afternoon Nutrition Break & Exibits | |
| 14:45:00 | 15:05:00 | Cardiac MRI: a short review of clinical use. | Dr. Helen Bishop |
| | | CMRI has limited access in NS and NB. What are the conditions where MRI is required for clinical decision making? Are there other modalities that can address many usual MRI clinical questions? What are the conditions where a cMRI is a "must have" | |

| | | versus "it would be good if"? When required, how is it best to access this test? | |
|----------|----------|---|-------------------|
| 15:05:00 | 15:15:00 | Audience Interaction & Participation | |
| 15:15:00 | 15:25:00 | Short Snapper: I'm starting and SGLT2i and my patient is on "other" diabetes drugs? What should I do? | Dr. Tom Ransom |
| 15:25:00 | 15:30:00 | Audience Interaction & Participation | |
| 15:30:00 | 15:40:00 | Short Snapper: My patient had "provoked AF"how long should I keep on an OAC? | Dr. John Sapp |
| 15:40:00 | 15:45:00 | Audience Interaction & Participation | |
| 15:45:00 | 16:00:00 | Meeting Wrap Up & Program Evaluation | Dr. Simon Jackson |

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Dalhousie University. You may claim a maximum of XX hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme.

